Michael Schickler - Purple Biotech Head of Clinical Operations
| KTOV Stock | ILA 28.10 2.30 8.91% |
Insider
Michael Schickler is Head of Clinical Operations of Purple Biotech since 2020.
| Age | 65 |
| Tenure | 4 years |
| Phone | 972 3 933 3121 |
| Web | http://www.kitovpharma.com |
Purple Biotech Management Efficiency
The company has return on total asset (ROA) of (0.0915) % which means that it has lost $0.0915 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.9204) %, meaning that it generated substantial loss on money invested by shareholders. Purple Biotech's management efficiency ratios could be used to measure how well Purple Biotech manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Yoni Barel | Azorim Investment Development | 32 | |
| Yoram Abraham | Scope Metals Group | 54 | |
| Alex Shatzir | Scope Metals Group | N/A | |
| Maor Duak | Menif Financial Services | 47 | |
| Yoav Tsabar | Unet Credit Finance | 70 | |
| Eliaz Omer | Scope Metals Group | N/A | |
| Sigal Halevy | Azorim Investment Development | N/A | |
| Ilan Toledano | Scope Metals Group | 52 | |
| Liat Strauss | Clal Insurance Enterprises | 45 | |
| Zvika CPA | Scope Metals Group | N/A | |
| Stanley ADV | Scope Metals Group | N/A | |
| Eran Cherninsky | Clal Insurance Enterprises | 61 | |
| Gilad Fishman | Scope Metals Group | 51 | |
| Alex Master | Scope Metals Group | N/A | |
| Gil CPA | Scope Metals Group | 56 | |
| Boaz Leshem | Scope Metals Group | 63 | |
| Hadar BreenWeiss | Clal Insurance Enterprises | 53 | |
| Nili Barda | Menif Financial Services | 52 | |
| Hila Conforti | Clal Insurance Enterprises | 60 | |
| Lilach Erez | Azorim Investment Development | N/A | |
| Levi Shtresler | Azorim Investment Development | 52 | |
Management Performance
| Return On Equity | -0.92 | |||
| Return On Asset | -0.0915 |
Purple Biotech Leadership Team
Elected by the shareholders, the Purple Biotech's board of directors comprises two types of representatives: Purple Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Purple. The board's role is to monitor Purple Biotech's management team and ensure that shareholders' interests are well served. Purple Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Purple Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Itzhak Israel, Chief Executive Officer & Director | ||
| Steven Steinberg, Independent Director | ||
| Gil BenMenachem, Vice President - Business Development | ||
| Michael Schickler, Head of Clinical Operations | ||
| CPA MBA, Strategic Director | ||
| Arie Weber, Independent Director | ||
| Bertrand Liang, Chief Medical Officer | ||
| Yisrael Gewirtz, Internal Auditor | ||
| Ran Tzror, Independent Director | ||
| Gil Efron, Deputy Chief Executive Officer, Chief Financial Officer | ||
| Simcha Rock, CFO, Director | ||
| Eric Rowinsky, Chairman of the Board | ||
| Ido Agmon, Independent Director | ||
| Gil CPA, Deputy CFO | ||
| Isaac Israel, CEO Director | ||
| Revital SternRaff, Independent Director | ||
| Avraham BenTzvi, General Counsel, Secretary | ||
| Hadas Reuveni, Founder and Chief Technology Officer of TyrNovo (a subsidiary) |
Purple Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Purple Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.92 | |||
| Return On Asset | -0.0915 | |||
| Operating Margin | (7.54) % | |||
| Shares Outstanding | 172.11 M | |||
| Shares Owned By Insiders | 0.12 % | |||
| Shares Owned By Institutions | 1.22 % | |||
| Price To Earning | (364.21) X | |||
| Price To Book | 1.27 X | |||
| Price To Sales | 16.36 X | |||
| Revenue | 1000 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Purple Biotech is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Purple Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Purple Biotech Stock. Highlighted below are key reports to facilitate an investment decision about Purple Biotech Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Purple Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Purple Stock refer to our How to Trade Purple Stock guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Complementary Tools for Purple Stock analysis
When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |